Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RegeneRx completes patient recruitment in Phase 2 dry eye drug trial
In total, the company has recruited 72 patients in the trial and expects to conclude treatment by its stipulated time line. RGN-259, a sterile, preservative-free topical eye drop
In total, the company has recruited 72 patients in the trial and expects to conclude treatment by its stipulated time line. RGN-259, a sterile, preservative-free topical eye drop
EpiPen and EpiPen Jr Auto-Injectors are intended for immediate self administration as emergency supportive therapy only. According to the guidelines given by the National Institute of Allergy and
Millennium offers information and tools to identify and resolve operational cost inefficiencies, patient safety compliance and cash-flow enhancement strategies through its subsidiaries. Millennium president Chris Amandola said they
eClinical Consulting offers services in data safety monitoring, adverse event reporting, statistical analysis, system integration, and study execution. Moreover, eClinical Consulting supports patient recruitment, IRB and study monitoring,
The agreement refers to ‘Azodyl’, a patented, 100% natural, probiotic dietary supplement which is used to reduce azotemia in dogs and cats with moderate to severe renal failure.
Anchen has 27 abbreviated new drug applications (ANDA) pending with the US Food and Drug Administration (FDA). Anchen expects to roll out around 8-10 niche generic products over
The nasal sprays are made from natural, homeopathic ingredients which aid in the relief of allergies and, cold and flu symptoms, claims the company. TheraBiogen CEO Kelly Hickel
Unifill EZMix syringes comprises two or more drug containers within a single glass barrel to store a combination of liquid stable or lyophilized drugs along with up to
The trial, which will be conducted in healthy male volunteers, is a combined single and multiple ascending dose safety, tolerability and pharmacokinetic trial. The company expects to evaluate
PSI-938 is an oral guanosine nucleotide analog polymerase inhibitor of HCV. Earlier in Nuclear study , PSI-938 showed potent antiviral activity and was generally safe and well tolerated,